Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)

• Status: Completed
• Trial end date: 2013-01-24
• Target enrollment: 0
• Participant gender: All

Summary

This study is a 2-year open label extension study to collect long term efficacy and safety data from patients who have completed the 24-weeks of study drug dosing in CL0600-020.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shire
• Collaborator: Nycomed Germany GmbH
• Treatments: Teduglutide

Criteria

Inclusion Criteria:

• must have completed 24 weeks of dosing of the CL0600-020 study

Exclusion Criteria:

• none